Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 12/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | QPCT | Q16769 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL1321133 | 1.00 | TBXAS1 (0.96) | TBXAS1KDM4ELMNAQPCTPRKCI | |
| Iodide SCHEMBL29082778 | 1.00 | TBXAS1 (0.96) | TBXAS1KDM4ELMNAQPCTPRKCI | |
| Iodide SCHEMBL16567961 | 1.00 | TBXAS1 (0.96) | TBXAS1KDM4ELMNAQPCTPRKCI | |
| Iodide SCHEMBL16163638 | 1.00 | TBXAS1 (0.96) | TBXAS1KDM4ELMNAQPCTPRKCI | |
| Iodide SCHEMBL633495 | 1.00 | TBXAS1 (0.96) | TBXAS1KDM4ELMNAQPCTPRKCI | |
| SCHEMBL304926 | 0.98 | TBXAS1 (1.00) | TBXAS1KDM4ELMNAQPCTPRKCI | |
| SCHEMBL413378 | 0.98 | TBXAS1 (1.00) | TBXAS1KDM4ELMNAQPCTPRKCI | |
| SCHEMBL284539 | 0.98 | TBXAS1 (1.00) | TBXAS1KDM4ELMNAQPCTPRKCI | |
| SCHEMBL4067377 | 0.98 | TBXAS1 (1.00) | TBXAS1KDM4ELMNAQPCTPRKCI | |
| SCHEMBL4062530 | 0.98 | TBXAS1 (1.00) | TBXAS1KDM4ELMNAQPCTPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305472-A1 | POLYIONIC NANOCLAYS | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2022-09-29 | — | — | US | disclosed |
| US-8652499-B2 | Medical antimicrobial composition and medical device comprising the same | TORAY INDUSTRIES, INC. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20110008403-A1 | MEDICAL ANTIMICROBIAL COMPOSITION AND MEDICAL DEVICE COMPRISING THE SAME | TORAY INDUSTRIES, INC. (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008403-A1 | MEDICAL ANTIMICROBIAL COMPOSITION AND MEDICAL DEVICE COMPRISING THE SAME | AAAS, MMS19, MSN | TBXAS1 1609/4885KDM4E 2208/4885LMNA 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.